Literature DB >> 10457868

Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.

A M van Heusden1, B C Fauser.   

Abstract

This study was performed to evaluate pituitary-ovarian recovery in the pill-free interval during use of three low-dose combined oral contraceptives (COC). Either the estrogen component or the progestin component was comparable in the study groups, to evaluate their relative influence. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels were measured and follicle number and size estimated by transvaginal sonography daily during the 7-day pill-free interval in 44 healthy volunteers using three different low-dose oral contraceptives. Healthy volunteers were enrolled using 20 micrograms ethinyl estradiol (EE) + 75 micrograms gestodene (GSD) (Harmonet, Wyeth-Lederle; n = 15), 20 micrograms EE + 150 micrograms desogestrel (DSG) (Mercilon, Organon n = 17), or 30 micrograms EE + 150 micrograms DSG (Marvelon, Organon, n = 12) given according to the usual regimen of one tablet daily during 3 weeks and 1 week pill-free interval. No ovulations were observed. Pituitary hormones were not statistically significantly different at the beginning of the pill-free interval between the study groups. FSH concentrations were significantly higher at the end of the pill-free interval in the 30 micrograms EE group compared with both 20 micrograms EE groups (7.0 [0.6-12.4] IU/L vs 4.9 [1.4-6.1] IU/L and 4.5 [2.4-7.4] IU/L; p = 0.001). In both 20 micrograms EE groups, a single persistent follicle (24 and 28 mm) was present in one subject. Follicle diameters were statistically significantly smaller at the beginning and at the end of the pill-free period in the 30 micrograms EE group compared with both 20 micrograms EE study groups. Dominant follicles (defined as follicle diameter > or = 10 mm) were observed at the end of the pill-free interval in both 20 micrograms EE groups (in 27% and 18% of women, respectively) but not in the 30 micrograms EE group. Finally, the area-under-the-curve for E2 was statistically significantly lower in the 30 micrograms EE group compared with both 20 micrograms EE groups. In conclusion, the EE content rather than the progestin component in the studied COC determined the extent of residual ovarian activity at the beginning of the pill-free interval. Dominant follicles were encountered only in the 20 micrograms EE study groups.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Desogestrel; Endocrine System; Ethinyl Estradiol; Family Planning; Follicle Stimulating Hormone--analysis; Genitalia; Genitalia, Female; Gestodene; Gonadotropins; Gonadotropins, Pituitary; Hormones; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Low-dose; Ovarian Effects; Ovary; Physiology; Research Methodology; Research Report; Urogenital System

Mesh:

Substances:

Year:  1999        PMID: 10457868     DOI: 10.1016/s0010-7824(99)00025-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  16 in total

1.  Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?

Authors:  Carla Schmitz; Silvina Bocca; Hind Beydoun; Laurel Stadtmauer; Sergio Oehninger
Journal:  J Assist Reprod Genet       Date:  2012-06-23       Impact factor: 3.412

Review 2.  Blood pressure and water regulation: understanding sex hormone effects within and between men and women.

Authors:  Megan M Wenner; Nina S Stachenfeld
Journal:  J Physiol       Date:  2012-10-01       Impact factor: 5.182

3.  Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.

Authors:  Alison B Edelman; Nichole E Carlson; Ganesh Cherala; Myrna Y Munar; Richard L Stouffer; Judy L Cameron; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2009-06-04       Impact factor: 3.375

4.  Mechanisms contributing to low orthostatic tolerance in women: the influence of oestradiol.

Authors:  Megan M Wenner; Ala' S Haddadin; Hugh S Taylor; Nina S Stachenfeld
Journal:  J Physiol       Date:  2013-02-11       Impact factor: 5.182

Review 5.  Ovarian follicular development during the use of oral contraception: a review.

Authors:  Angela R Baerwald; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2004-01

6.  St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.

Authors:  Liane Will-Shahab; Steffen Bauer; Ullrich Kunter; Ivar Roots; Axel Brattström
Journal:  Eur J Clin Pharmacol       Date:  2008-11-18       Impact factor: 2.953

7.  Effects of continuous versus cyclical oral contraception: a randomized controlled trial.

Authors:  Richard S Legro; Jaimey G Pauli; Allen R Kunselman; Juliana W Meadows; James S Kesner; Richard J Zaino; Laurence M Demers; Carol L Gnatuk; William C Dodson
Journal:  J Clin Endocrinol Metab       Date:  2007-12-04       Impact factor: 5.958

8.  Women's interest in visual sexual stimuli varies with menstrual cycle phase at first exposure and predicts later interest.

Authors:  Kim Wallen; Heather A Rupp
Journal:  Horm Behav       Date:  2009-12-23       Impact factor: 3.587

9.  Oral Contraceptive Use, Muscle Sympathetic Nerve Activity, and Systemic Hemodynamics in Young Women.

Authors:  Ronee E Harvey; Emma C Hart; Nisha Charkoudian; Timothy B Curry; Jason R Carter; Qi Fu; Christopher T Minson; Michael J Joyner; Jill N Barnes
Journal:  Hypertension       Date:  2015-06-22       Impact factor: 10.190

10.  Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder.

Authors:  Lesley L Breech; Paula K Braverman
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.